Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes at Week 6 - 1 versus 2 doses;The incidence of solicited local reactogenicity signs and symptoms;The incidence of solicited systemic reactogenicity signs and symptoms;The incidence of unsolicited adverse events in study participants.;The occurrence of adverse events of special interest (AESI), including potentially immune mediated disorders (pIMD);The occurrence of serious adverse events (SAE).

Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes at Week 6 - 1 versus 2 doses;The incidence of solicited local reactogenicity signs and symptoms;The incidence of solicited systemic reactogenicity signs and symptoms;The incidence of unsolicited adverse events in study participants.;The occurrence of adverse events of special interest (AESI), including potentially immune mediated disorders (pIMD);The occurrence of serious adverse events (SAE).